Last reviewed · How we verify

indacaterol/glycopyrronium 110/50 Breezhaler®

Wouter H. van Geffen · FDA-approved active Small molecule

indacaterol/glycopyrronium 110/50 Breezhaler® is a Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Small molecule drug developed by Wouter H. van Geffen. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Ultibro.

Indacaterol is a long-acting beta-2 agonist and glycopyrronium is an anticholinergic that together relax airway smooth muscle and reduce mucus secretion to improve airflow in chronic obstructive pulmonary disease.

Indacaterol is a long-acting beta-2 agonist and glycopyrronium is an anticholinergic that together relax airway smooth muscle and reduce mucus secretion to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameindacaterol/glycopyrronium 110/50 Breezhaler®
Also known asUltibro
SponsorWouter H. van Geffen
Drug classLong-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)
TargetBeta-2 adrenergic receptor; Muscarinic M3 acetylcholine receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

Indacaterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting up to 24 hours. Glycopyrronium blocks muscarinic acetylcholine receptors, providing additional bronchodilation and reducing mucus production. The combination provides dual bronchodilation through complementary mechanisms for sustained airway opening.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about indacaterol/glycopyrronium 110/50 Breezhaler®

What is indacaterol/glycopyrronium 110/50 Breezhaler®?

indacaterol/glycopyrronium 110/50 Breezhaler® is a Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) drug developed by Wouter H. van Geffen, indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does indacaterol/glycopyrronium 110/50 Breezhaler® work?

Indacaterol is a long-acting beta-2 agonist and glycopyrronium is an anticholinergic that together relax airway smooth muscle and reduce mucus secretion to improve airflow in chronic obstructive pulmonary disease.

What is indacaterol/glycopyrronium 110/50 Breezhaler® used for?

indacaterol/glycopyrronium 110/50 Breezhaler® is indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes indacaterol/glycopyrronium 110/50 Breezhaler®?

indacaterol/glycopyrronium 110/50 Breezhaler® is developed and marketed by Wouter H. van Geffen (see full Wouter H. van Geffen pipeline at /company/wouter-h-van-geffen).

Is indacaterol/glycopyrronium 110/50 Breezhaler® also known as anything else?

indacaterol/glycopyrronium 110/50 Breezhaler® is also known as Ultibro.

What drug class is indacaterol/glycopyrronium 110/50 Breezhaler® in?

indacaterol/glycopyrronium 110/50 Breezhaler® belongs to the Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) class. See all Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) drugs at /class/long-acting-beta-2-agonist-long-acting-muscarinic-antagonist-laba-lama-combination.

What development phase is indacaterol/glycopyrronium 110/50 Breezhaler® in?

indacaterol/glycopyrronium 110/50 Breezhaler® is FDA-approved (marketed).

What are the side effects of indacaterol/glycopyrronium 110/50 Breezhaler®?

Common side effects of indacaterol/glycopyrronium 110/50 Breezhaler® include Tremor, Headache, Palpitations, Dry mouth, Cough, Nasopharyngitis.

What does indacaterol/glycopyrronium 110/50 Breezhaler® target?

indacaterol/glycopyrronium 110/50 Breezhaler® targets Beta-2 adrenergic receptor; Muscarinic M3 acetylcholine receptor and is a Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination).

Related